OS Therapies Unveils Two New Tunable Antibody Drug Conjugate Therapeutics

OS Therapies, a clinical-stage biopharmaceutical company listed on the NYSE American under the ticker OSTX, recently announced significant advancements in the development of two innovative Antibody Drug Conjugate (ADC) therapeutic candidates. These developments utilize the company's proprietary SiLinker™ technology. The promising candidates have shown positive results in target engagement tests, indicating their potential therapeutic efficacy. These new ADC constructs are aimed at treating various types of cancer, including Breast, Lung, Gastric, Ovarian, Fallopian Tube, and Primary Peritoneal cancers.

The company is making steady progress in enhancing its tADC platform through a series of product development milestones designed to minimize risk. OS Therapies plans to out-license certain candidates and components, especially the pH-sensitive SiLinker™, to strategic partners whose pipelines align with these innovations. Among its achievements, the company’s first tADC asset, OST-tADC-FRα-H, has already demonstrated proof of concept in animal models of ovarian cancer. With the addition of the two new constructs to its pipeline, OS Therapies aims to be a leading provider of intellectual property for novel therapeutic product development.

In addition to these developments, OS Therapies continues to focus on its OST-HER2 cancer vaccine platform. This off-the-shelf immunotherapy is being developed for canines with osteosarcoma and for humans with osteosarcoma and other HER2-positive cancers, such as breast and colorectal cancers.

OS Therapies is primarily dedicated to oncology, with a particular focus on discovering, developing, and commercializing treatments for Osteosarcoma (OS) and other solid tumors. Their leading asset, OST-HER2, is an immunotherapy designed to trigger a potent immune response against the HER2 protein by utilizing immune-stimulatory Listeria bacteria. The company has concluded enrollment for a Phase 2b clinical trial involving 41 patients with resected, recurrent osteosarcoma. Results from this trial are anticipated in the fourth quarter of 2024. Additionally, OST-HER2 has completed a Phase 1 clinical study, which primarily involved breast cancer patients, and has shown robust preclinical efficacy across various breast cancer models.

Furthering its innovative approach, OS Therapies is also developing a next-generation ADC platform termed tunable ADC (tADC), which features customizable antibody-linker-payload candidates. This platform capitalizes on the company's unique silicone linker technology, which allows for the delivery of multiple payloads.

OS Therapies continues to leverage its scientific expertise and proprietary technologies to expand its therapeutic pipeline, aiming to improve outcomes for patients with challenging cancers. As the company advances its clinical programs and partnerships, it is well-positioned to make significant contributions to the field of oncology.